Search
SOLACI Congress
HomeCONGRESSInternational Congresses

International Congresses

View Category
Antithrombotic Anticoagulants

ESC 2019 | AFIRE: Monotherapy with Rivaroxaban in Atrial Fibrillation and Stable CAD

In patients with atrial fibrillation and stable coronary artery disease who have not had revascularization procedures in...
solaci -
Learn More
Mitral valve

ESC 2019 | MITRA-FR: 2-Year Outcomes of One of the Largest Studies on MitraClip

Negative one-year outcomes of Mitra-FR led to several discussions and hypothesis, especially after the COAPT was published...
solaci -
Learn More
Other

ESC 2019 | DAPA-HF: Dapagliflozin Shows Benefit for All Subgroups

Dapagliflozin (a sodium glucose co-transporter 2 inhibitor), when indicated concomitantly with standard therapy, reduces significantly the...
solaci -
Learn More
Chronic Ischemic cardiopathy

ESC 2019 | New European Guidelines on “Chronic Coronary Syndromes”

In Paris, during the European Society of Cardiology (ESC) Congress 2019 Scientific Sessions, new guidelines for the...
solaci -
Learn More
Acute coronary syndromes

ESC 2019 | COMPLETE: Definitive Evidence for Infarction with Multivessel Disease

For patients with ST-segment elevation acute myocardial infarction and multivessel disease beyond the culprit artery, complete revascularization...
solaci -
Learn More
Acute coronary syndromes

ESC 2019 | CONDI-2ERIC-PPCI: Final Blow Against Ischemic Pre-Conditioning in Primary Angioplasty

Remote ischemic conditioning does not offer any clinical benefit to patients with ST-segment elevation acute myocardial infarction...
solaci -
Learn More
Acute coronary syndromes

ESC 2019 | ISAR-REACT 5 | Which Is Better in ACS, Prasugrel or Ticagrelor?

Courtesy of Dr. Carlos Fava. The benefit of dual antiplatelet therapy in acute coronary syndromes (ACS) has been...
solaci -
Learn More
ESC 2019

ESC 2019

Here you will find the highlights of the ESC 2019 Congres, held on August 31st to September...
solaci -
Learn More

SOLACI is the reference organization for Latin American cardiovascular interventionism.

Last News

Long-Term Cardiovascular Risk in Patients With ANOCA: A Clinical Reality to Consider?

Dr. Omar Tupayachi - 0
Chronic stable angina (CSA) remains one of the most frequent reasons for referral to diagnostic coronary angiography (CAG). In a substantial proportion of these...

Perforation Management in Bifurcations: Bench Testing of Bailout with Covered Stents

Dr. Omar Tupayachi - 0
Coronary perforations during PCI are one of the most dreaded complications in interventional cardiology, especially in bifurcations. Though rate, this critical situation requires an...

Transapical TMVR in High Risk Patients: Intrepid 5-Year Outcomes

Dr. Omar Tupayachi - 0
Moderate to severe mitral valve regurgitation (MR) continues is still a high prevalence condition with bad prognosis, particularly among the elderly with left ventricular...

Institutional News

SOLACI Wishes You Happy Holidays

solaci - 0
From the heart, Happy Holidays! The Latin American Society of Interventional Cardiology wishes all its members and the medical community across the continent a very Merry Christmas...

Condolences on the passing of Cristiam Arancibia

solaci - 0
The Latin American Society of Interventional Cardiology deeply mourns the passing of Lic. Cristiam Arancibia, first Director of the Chapter of Technicians and Nurses,...

Watch Again: Pulmonary Embolism in 2025 — Risk Stratification and Novel Therapeutic Approaches

solaci - 0
Our webinar “Pulmonary Embolism in 2025: Risk Stratification and Novel Therapeutic Approaches” is now available to watch. The session took place on November 25,...

Access

Adolfo Alsina 2653 · Piso 2H · CABA · Buenos Aires · Argentina · (5411) 4954 7173 · info@solaci.org · solaci.org · Terms of Use -Privacy Policy